Lawsuit filed for Investors who lost money with shares of DexCom, Inc. (NASDAQ: DXCM)

An investor, who purchased shares of DexCom, Inc. (NASDAQ: DXCM), filed a lawsuit over alleged violations of Federal Securities Laws by DexCom, Inc. in connection with certain allegedly false and misleading statements made between July 26, 2024 and September 17, 2025.

Investors who purchased shares of DexCom, Inc. (NASDAQ: DXCM) have certain options and for certain investors are short and strict deadlines running. Deadline: December 26, 2025. NASDAQ: DXCM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Diego, CA based DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. . The Company's products include, inter alia, the Dexcom G6 and Dexcom G7 systems, which DexCom launched in 2018 and 2023, respectively. DexCom, Inc. reported that its annual Total Revenue rose from over $3.62 billion in 2023 to ovedr $4.03 billion in 2024, and that its Net Income increased from $541.5 million in 2023 in 2023 to $576.2 million in 2024.

On March 7, 2025, DexCom, Inc disclosed in an United States Securities and Exchange Commission filing that, three days earlier, it had received a warning letter (the "Warning Letter") from the FDA related to concerns about manufacturing processes and quality management systems at certain of the Company's facilities.

On March 25, 2025, the FDA published the Warning Letter on its website, revealing that DexCom had "adulterated" its G6 and G7 products by "modif[ying] the G6 and G7 sensors" without prior regulatory approval, thereby subjecting the devices to "larger inaccuracies" that "cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions."

On September 8, 2025, equity research firm Oppenheimer issued a note downgrading DexCom's rating to "perform" from "outperform." Oppenheimer also removed its $102.00 price target on the Company's stock. Oppenheimer cited, inter alia, patient concern with the G7's poor accuracy, failed sensor insertions, abrupt stoppages, and other issues, noting that "field checks point to rising concerns about G7 accuracy/performance."

Then, on September 18, 2025, Hunterbrook published a report addressing DexCom, entitled "Dexcom's Fatal Flaws". The Hunterbrook report revealed, inter alia, that issues and health risks posed by adulterated G7 devices were more severe and widespread than previously disclosed, citing FDA documents it had procured via a Freedom of Information Act request, as well as various comments from doctors, patients and their families, and former DexCom employees. Specifically, the Hunterbrook report found that "G7 users have been hospitalized and died" following inaccurate glucose readings, linking these deadly incidents to adulterated G7 devices and Defendants' willingness to cut corners to meet margins.

Shares of DexCom, Inc. (NASDAQ: DXCM) declined from $93.25 per share on February 18, 2025, to as low as $56.45 per share on October 31, 2025

The plaintiff claims that between July 26, 2024 and September 17, 2025, the Defendants made false and/or misleading statements and/or failed to disclose that DexCom had made material design changes to the G6 and G7 unauthorized by the United States Food and Drug Administration (the "FDA"), that the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings, that accordingly, Defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated, that the Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices, that all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm, and that as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Those who purchased shares of DexCom, Inc. (NASDAQ: DXCM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.